|
neutrophil mediated immunity
|
GO_0002446 |
[Any process involved in the carrying out of an immune response by a neutrophil.] |
|
SARS coronavirus TW-GD5
|
NCBITaxon_264382 |
|
|
SARS coronavirus TW-YM1
|
NCBITaxon_264383 |
|
|
endoplasmic reticulum quality control compartment
|
GO_0044322 |
[A subcompartment of the endoplasmic reticulum in which proteins with improper or incorrect folding accumulate. Enzymes in this compartment direct proteins with major folding problems to translocation to the cytosol and degradation, and proteins with minor folding problems to the ER, to interact with chaperon proteins.] |
|
ticagrelor
|
CHEBI_68558 |
[A triazolopyrimidine that is an adenosine isostere; the cyclopentane ring is similar to ribose and the nitrogen-rich [1,2,3]triazolo[4,5-d]pyrimidine moiety resembles the nucleobase adenine. A platelet aggregation inhibitor which is used for prevention of thromboembolic events in patients with acute coronary syndrome.] |
|
icatibant
|
CHEBI_68556 |
[A ten-membered synthetic oligopeptide consisting of D-Arg, Arg, Pro, Hyp, Gly, Thi, Ser, D-Tic, Oic, and Arg residues joined in sequrence. A bradykinin receptor antagonist used as its acetate salt for the treatment of acute attacks of hereditary angioedema in adult patients.] |
|
production of molecular mediator of immune response
|
GO_0002440 |
[The synthesis or release of any molecular mediator of the immune response, resulting in an increase in its intracellular or extracellular levels.] |
|
ceftolozane
|
CHEBI_134719 |
[A fifth-generation cephalosporin antibiotic having (5-amino-4-{[(2-aminoethyl)carbamoyl]amino}-1-methyl-1H-pyrazol-2-ium-2-yl)methyl and [(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino side groups located at positions 3 and 7 respectively; developed for the treatment of infections with gram-negative bacteria that have become resistant to conventional antibiotics.] |
|
atherosclerosis
|
DOID_1936 |
[Build-up of fatty material and calcium deposition in the arterial wall resulting in partial or complete occlusion of the arterial lumen.] |
|
arteriosclerotic cardiovascular disease
|
DOID_2348 |
[Cardiovascular disease resulting from arteriosclerosis.] |
|
cellular aldehyde metabolic process
|
GO_0006081 |
[The chemical reactions and pathways involving aldehydes, any organic compound with the formula R-CH=O, as carried out by individual cells.] |
|
Renal Replacement Therapy
|
NCIT_C126400 |
[Treatments that substitute for the blood-filtering function of the kidneys. It includes dialysis (hemodialysis or peritoneal dialysis), hemofiltration, and hemodiafiltration. Kidney transplant may also be considered a renal replacement therapy.] |
|
therapeutic procedure
|
OGMS_0000112 |
[A treatment whose completion is hypothesized by a health care provider to eliminate a disorder or to alleviate the signs and symptoms of a disorder or pathological process.] |
|
immaterial entity
|
BFO_0000141 |
|
|
independent continuant
|
BFO_0000004 |
[b is an independent continuant = Def. b is a continuant which is such that there is no c and no t such that b s-depends_on c at t. (axiom label in BFO2 Reference: [017-002])] |
|
one-dimensional continuant fiat boundary
|
BFO_0000142 |
|
|
continuant fiat boundary
|
BFO_0000140 |
[b is a continuant fiat boundary = Def. b is an immaterial entity that is of zero, one or two dimensions and does not include a spatial region as part. (axiom label in BFO2 Reference: [029-001])] |
|
SARS coronavirus TW10
|
NCBITaxon_258963 |
|
|
SARS coronavirus TW11
|
NCBITaxon_258964 |
|
|
relational quality
|
BFO_0000145 |
[b is a relational quality = Def. for some independent continuants c, d and for some time t: b quality_of c at t & b quality_of d at t. (axiom label in BFO2 Reference: [057-001])] |